EP1061921A4 - Antagonistes du recepteur de la vitronectine - Google Patents

Antagonistes du recepteur de la vitronectine

Info

Publication number
EP1061921A4
EP1061921A4 EP99909952A EP99909952A EP1061921A4 EP 1061921 A4 EP1061921 A4 EP 1061921A4 EP 99909952 A EP99909952 A EP 99909952A EP 99909952 A EP99909952 A EP 99909952A EP 1061921 A4 EP1061921 A4 EP 1061921A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99909952A
Other languages
German (de)
English (en)
Other versions
EP1061921A1 (fr
Inventor
William H Miller
John G Gleason
Dirk Heerding
James M Samanen
Irene N Uzinskas
Peter J Manley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1061921A1 publication Critical patent/EP1061921A1/fr
Publication of EP1061921A4 publication Critical patent/EP1061921A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP99909952A 1998-03-10 1999-03-10 Antagonistes du recepteur de la vitronectine Withdrawn EP1061921A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US77610P 1998-03-10
US9606398P 1998-08-11 1998-08-11
US96063P 1998-08-11
PCT/US1999/005232 WO1999045927A1 (fr) 1998-03-10 1999-03-10 Antagonistes du recepteur de la vitronectine

Publications (2)

Publication Number Publication Date
EP1061921A1 EP1061921A1 (fr) 2000-12-27
EP1061921A4 true EP1061921A4 (fr) 2005-03-30

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99909952A Withdrawn EP1061921A4 (fr) 1998-03-10 1999-03-10 Antagonistes du recepteur de la vitronectine

Country Status (24)

Country Link
EP (1) EP1061921A4 (fr)
JP (1) JP2002506033A (fr)
KR (1) KR20010041812A (fr)
CN (1) CN1299282A (fr)
AP (1) AP2000001898A0 (fr)
AR (1) AR015241A1 (fr)
AU (1) AU758498B2 (fr)
BG (1) BG104824A (fr)
BR (1) BR9908636A (fr)
CA (1) CA2323208A1 (fr)
CO (1) CO5080762A1 (fr)
DZ (1) DZ2741A1 (fr)
EA (1) EA200000921A1 (fr)
HU (1) HUP0101143A3 (fr)
ID (1) ID26223A (fr)
IL (1) IL138245A0 (fr)
NO (1) NO20004503L (fr)
OA (1) OA12189A (fr)
PE (1) PE20000323A1 (fr)
PL (1) PL342881A1 (fr)
SK (1) SK13292000A3 (fr)
TR (1) TR200002625T2 (fr)
UY (2) UY25421A1 (fr)
WO (1) WO1999045927A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
WO2001096307A2 (fr) 2000-06-15 2001-12-20 Pharmacia Corporation Acides alcanoiques cycloalkyles comme antagonistes d'integrines
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20070275956A1 (en) * 2003-10-14 2007-11-29 Lohray Braj B Novel Heterocyclic Compounds
US7678810B2 (en) * 2004-03-05 2010-03-16 Taisho Pharmaceutical Co., Ltd Thiazole derivative
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006115652A1 (fr) 2005-04-20 2006-11-02 Janssen Pharmaceutica, N.V. Modulateurs de la thrombine a base de pyridine n-oxyde fluoree et procede de n-oxydation d'heteroaryles azotes
PL3040329T3 (pl) * 2013-08-29 2019-04-30 Kyoto Pharma Ind Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości
EP3050878B1 (fr) 2013-09-24 2021-10-27 FUJIFILM Corporation Nouveau composé contenant de l'azote ou son sel, ou son complexe métallique
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024124A1 (fr) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de la vitronectine
WO1997024122A1 (fr) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024124A1 (fr) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de la vitronectine
WO1997024122A1 (fr) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9945927A1 *

Also Published As

Publication number Publication date
AP2000001898A0 (en) 2000-09-30
CN1299282A (zh) 2001-06-13
UY25421A1 (es) 2001-07-31
AR015241A1 (es) 2001-04-18
JP2002506033A (ja) 2002-02-26
ID26223A (id) 2000-12-07
CO5080762A1 (es) 2001-09-25
PL342881A1 (en) 2001-07-16
AU2903399A (en) 1999-09-27
BG104824A (en) 2001-05-31
NO20004503D0 (no) 2000-09-08
OA12189A (en) 2006-05-09
CA2323208A1 (fr) 1999-09-16
DZ2741A1 (fr) 2003-09-08
KR20010041812A (ko) 2001-05-25
AU758498B2 (en) 2003-03-20
EA200000921A1 (ru) 2001-04-23
HUP0101143A2 (hu) 2001-08-28
SK13292000A3 (sk) 2001-06-11
BR9908636A (pt) 2002-01-08
EP1061921A1 (fr) 2000-12-27
WO1999045927A1 (fr) 1999-09-16
TR200002625T2 (tr) 2000-12-21
UY25519A1 (es) 1999-12-13
HUP0101143A3 (en) 2002-12-28
PE20000323A1 (es) 2000-05-24
NO20004503L (no) 2000-10-10
IL138245A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
CY2576B1 (en) Vitronectin receptor antagonists
EP1105389A4 (fr) Antagonistes de recepteurs d'integrine
IL130760A0 (en) Vitronectin receptor antagonists
EP1000031A4 (fr) Antagonistes du recepteur de vitronectine
PL342881A1 (en) Vitronectin receptor antagonists
IL135189A0 (en) Vitronectin receptor antagonist
IL135028A0 (en) Vitronectin receptor antagonists
IL135188A0 (en) Vitronectin receptor antagonist
EG24025A (en) Vitronectin receptor antagonist
IL148043A0 (en) Novel integrin receptor antagonists
IL146146A0 (en) Integrin receptor antagonists
GC0000203A (en) Vitronectin receptor antagonists
IL141163A0 (en) Vitronectin receptor antagonists
GB9810182D0 (en) Vitronectin receptor antagonists
GB9810882D0 (en) Vitronectin receptor antagonists
GB9822331D0 (en) Vitronectin receptor antagonists
GB9807384D0 (en) Vitronectin receptor antagonists
GB9807382D0 (en) Vitronectin receptor antagonists
GB9812686D0 (en) Vitronectin receptor antagonists
GB9810892D0 (en) Vitronectin receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists
GB9815803D0 (en) Vitronectin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
ZA991884B (en) Vitronectin receptor antagonists.
HK1038180A (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 20001009;SI PAYMENT 20001009

A4 Supplementary search report drawn up and despatched

Effective date: 20050216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050512

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1035319

Country of ref document: HK